<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605993</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-PNH-201</org_study_id>
    <secondary_id>2015-002674-20</secondary_id>
    <nct_id>NCT02605993</nct_id>
  </id_info>
  <brief_title>A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <official_title>A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability and efficacy of
      multiple IV doses of ALXN1210 administered to complement inhibitor treatment-naïve patients
      with PNH.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety as measured by change in the number of treatment-emergent and related adverse events as assessed by CTCAE (v4.03).</measure>
    <time_frame>Treatment Period (36 weeks) and Follow-up Period (week 36 to week 144)</time_frame>
    <description>Safety will be assessed as the reported incidence, number and severity of AEs, SAEs or AE-related discontinuation from the study, change from baseline in vital signs (body weight, blood pressure, heart rate), out of reference range laboratory results (serum chemistries including renal function, hematology, coagulation) and ECG assessments through week 36.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as measured by the percentage change in lactate dehydrogenase or LDH levels from baseline to Day 253 during treatment with ALXN1210.</measure>
    <time_frame>36 weeks</time_frame>
    <description>Percentage change in serum LDH levels (IU/L) from Baseline to week 36.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximal concentration of ALXN1210 in blood (tmax)</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the plasma concentration versus time Curve (AUC) of ALXN1210</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of ALXN1210</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALXN1210 elimination half-life (t1/2) in blood</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in concentration of complement factor 5 (C5)</measure>
    <time_frame>Treatment Period (36 weeks) and Follow-up Period (week 36 to week 144)</time_frame>
    <description>Pharmacodynamic (PD) activity of ALXN1210 will be assessed by changes from baseline in complement related and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum levels of terminal complement activity</measure>
    <time_frame>Treatment Period (36 weeks) and Follow-up Period (week 36 to week 144)</time_frame>
    <description>Pharmacodynamic (PD) activity of ALXN1210 will be assessed by changes from baseline in complement related and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of antibodies against ALXN1210</measure>
    <time_frame>Up to 144 weeks</time_frame>
    <description>Assessment of anti-ALXN1210 antibodies (whether detectable, and titers if positive) from baseline through end of study [Time Frame: Treatment Period through Follow-up Period (week 36 to week 144)]</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>PNH</condition>
  <arm_group>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug- ALXN1210</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug- ALXN1210</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug- ALXN1210</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug- ALXN1210</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Study Drug- ALXN1210</intervention_name>
    <description>Cohort 1: ascending dose escalation to therapeutic dose level
At Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to &lt; 60 kg: 3000 mg every 8 weeks
≥ 60 to &lt; 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks</description>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Study Drug- ALXN1210</intervention_name>
    <description>Cohort 2: ascending dose escalation to therapeutic dose level
At Day 463, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to &lt; 60 kg: 3000 mg every 8 weeks
≥ 60 to &lt; 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks</description>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Study Drug- ALXN1210</intervention_name>
    <description>Cohort 3: ascending dose escalation to therapeutic dose level
At Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to &lt; 60 kg: 3000 mg every 8 weeks
≥ 60 to &lt; 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks</description>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Study Drug- ALXN1210</intervention_name>
    <description>Cohort 4: ascending dose escalation to therapeutic dose level</description>
    <arm_group_label>Study Drug- ALXN1210 -Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age

          2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry

          3. Documented meningococcal vaccination not more than 3 years prior to dosing

          4. Female patients of childbearing potential must use highly effective contraception
             starting at screening and continuing until at least 8 months after the last dose of
             ALXN1210.

          5. Willing and able to give written informed consent and comply with the study visit
             schedule

        Exclusion Criteria:

          1. Treatment with a complement inhibitor at any time

          2. Females who are pregnant, breastfeeding or who have a positive pregnancy test at
             screening or Day 1

          3. Participation in an interventional clinical study within 30 days before initiation of
             dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on
             Day 1, or within 5 half-lives of the investigational product, whichever is greater

          4. History of allergy to excipients of ALXN1210 or known allergy to Chinese hamster
             ovary (CHO) cell proteins

          5. Inability to comply with study requirements

          6. History of any clinically significant cardiac, hepatic, immunologic, pulmonary, or
             rheumatoid disease that, in the Investigator's judgment, would preclude participation

          7. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make
             the patient unsuitable for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Quebec</city>
        <zip>HIT 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lyon</city>
        <state>Pierre-Bénite</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Taipei City</city>
        <zip>1002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Airdrie</city>
        <state>North Lanarkshire</state>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>November 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>complement inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
